LAVIPHARM S.A. NA EO 1 risk profile
36 Normal where most of the sector sits
Measured 21 October 2026 from BXA0's filed statements. Recomputed nightly.
36 (Normal), driven by Cash conversion at 52, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 47 | Elevated | Stable | Average daily turnover — $3.9K |
| Operating pressure | 26 | Normal | Easing | Operating-margin drift — +4.8 percentage points |
| Cash conversion | 52 | Elevated | Easing | Capital spending against operating cash — 0.69x |
| Leverage and coverage | 36 | Normal | Easing | Current ratio — 1.21x |
| Competitive position | 34 | Normal | Stable | R&D-intensity gap against peers — -28.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for LAVIPHARM S.A. NA EO 1